We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+15.6%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$8.4B
AUM Growth
+$1.66B
(+25%)
Cap. Flow
+$1.33B
Cap. Flow
% of AUM
15.85%
Top 10 Holdings %
Top 10 Hldgs %
61.33%
Holding
510
New
182
Increased
113
Reduced
52
Closed
146
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$79.7M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$74.4M |
| 3 |
Kenvue
KVUE
|
+$65.3M |
| 4 |
e.l.f. Beauty
ELF
|
+$51.7M |
| 5 |
GSK
GSK
|
+$46.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$96.3M |
| 2 |
EXAS
Exact Sciences
EXAS
|
+$56.4M |
| 3 |
PTC Therapeutics
PTCT
|
+$34.5M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$28M |
| 5 |
MongoDB
MDB
|
+$23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.56% |
| 2 | Technology | 5.44% |
| 3 | Consumer Discretionary | 5.13% |
| 4 | Consumer Staples | 2.69% |
| 5 | Communication Services | 1.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Allegion
ALLE
$14.4B
| $297K | ﹤0.01% |
+1,866
| New | +$311K |
|
277
AvalonBay Communities
AVB
$26.8B
| $297K | ﹤0.01% |
+1,638
| New | +$297K |
|
278
Cognex
CGNX
$11.5B
| $297K | ﹤0.01% |
+8,242
| New | +$334K |
|
279
InterDigital
IDCC
$8.87B
| $296K | ﹤0.01% |
+931
| New | +$329K |
|
|
TPC
280
Tutor Perini Cor
TPC
$5.12B
| $296K | ﹤0.01% |
+4,416
| New | +$290K |
|
|
ARIS
281
Aris Mining
ARIS
$3.53B
| $296K | ﹤0.01% |
+18,210
| New | +$224K |
|
282
Palomar
PLMR
$3.57B
| $295K | ﹤0.01% |
2,192
-369
| -14% | -$45K |
|
283
Sysco
SYY
$40B
| $295K | ﹤0.01% |
+4,007
| New | +$305K |
|
284
CME Group
CME
$95.7B
| $295K | ﹤0.01% |
1,081
-1,356
| -56% | -$368K |
|
285
nVent Electric
NVT
$26.9B
| $295K | ﹤0.01% |
+2,892
| New | +$300K |
|
286
Interactive Brokers
IBKR
$39.2B
| $295K | ﹤0.01% |
+4,582
| New | +$307K |
|
287
Lazard
LAZ
$4.3B
| $294K | ﹤0.01% |
+6,064
| New | +$303K |
|
288
Ambarella
AMBA
$3.86B
| $294K | ﹤0.01% |
+4,148
| New | +$335K |
|
289
Home BancShares
HOMB
$6.19B
| $293K | ﹤0.01% |
+10,559
| New | +$293K |
|
290
Huntington Bancshares
HBAN
$35.3B
| $293K | ﹤0.01% |
+16,906
| New | +$277K |
|
291
Calix
CALX
$2.4B
| $293K | ﹤0.01% |
+5,537
| New | +$323K |
|
292
Cincinnati Financial
CINF
$27.3B
| $293K | ﹤0.01% |
+1,791
| New | +$290K |
|
293
Emcor
EME
$36.1B
| $292K | ﹤0.01% |
+478
| New | +$310K |
|
294
Comfort Systems
FIX
$60B
| $292K | ﹤0.01% |
+313
| New | +$289K |
|
295
Global Payments
GPN
$22.5B
| $292K | ﹤0.01% |
+3,770
| New | +$303K |
|
296
HCW Biologics
HCWB
$5.48M
| $291K | ﹤0.01% |
+50,030
| New | +$850K |
|
297
International Bancshares
IBOC
$4.63B
| $291K | ﹤0.01% |
+4,384
| New | +$297K |
|
298
Mueller Industries
MLI
$15.2B
| $291K | ﹤0.01% |
+5,072
| New | +$273K |
|
299
GeneDx Holdings
WGS
$2.24B
| $288K | ﹤0.01% |
+2,216
| New | +$304K |
|
300
Enpro
NPO
$7.14B
| $286K | ﹤0.01% |
+1,337
| New | +$296K |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q4 2025 Portfolio in Review
As of Q4 2025, Armistice Capital held 510 positions worth $8.4B, up 25% from $6.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Armistice Capital deployed $1.33B of net new capital in Q4 2025, opening 182 new positions and adding to 113 existing holdings. Its largest new stake was Kenvue: 3,992,196 shares worth $68.9M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $96.3M trimmed.
- Armistice Capital's largest Q4 2025 buy was Kenvue: 3,992,196 shares worth $68.9M.
- Armistice Capital added most to Agios Pharmaceuticals in Q4 2025, an estimated $79.7M increase.
- Armistice Capital's biggest Q4 2025 reduction was Travere Therapeutics, cutting an estimated $96.3M.
- Armistice Capital fully exited Exact Sciences in Q4 2025, selling an estimated $56.4M.
- Armistice Capital's ten largest holdings make up 61% of its $8.4B portfolio in Q4 2025.
- Armistice Capital opened 182 new positions and closed 146 in Q4 2025.
- Armistice Capital's portfolio value rose 25% quarter-over-quarter to $8.4B.
Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.